HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Warlow, C. Search for Related Content PubMed Articles by Warlow, C.

Not Such a Bright Idea: The Uk Risk-Sharing Scheme for Beta Interferon and Glatiramer Acetate in Multiple Sclerosis

Department of Clinical Neurosciences, Edinburgh, UK; Email: cpw{at}skull.dcn.ed.ac.uk

EXTRACT

UK neurologists have been slow to prescribe beta interferon and other potentially disease-modifying drugs for multiple sclerosis (MS). We have been constrained by our notorious conservatism, which is in part based on our demand for good evidence before changing practice, particularly when it comes to very expensive therapeutic interventions such as beta interferon. But there has been another constraint – the UK National Health Service (NHS) has a centralized command and control system (which I personally rather approve of) that would not sanction the prescription of beta interferon because of its very high cost. After all, to prescribe even just to those patients conforming to the Association of British Neurologists (ABN) guidelines would cost roughly £120 million per annum, enough to fund about 1200 new consultant neurologists (which would quadruple our present number), or 4000 physiotherapists, or 8000 medical secretaries. It is all very well for individual neurologists to stamp their ...

[PDF of this article]